亞獅康&莊偉裕教授 開發dihydroorotate dehydrogenase (DHODH) 抑制劑(ASLAN003) 治療AML

亞獅康攜手星國學術機構，合作研究ASLAN003抗癌療法 MoneyDJ新聞 2017-03-02 10:16:57 記者 新聞中心 報導專注免疫療法與標靶抗癌藥物開發之生技公司亞獅康-KY(6497)今(2)日宣佈，公司將與新加坡癌症科學研究所(CSI)和新加坡國立大學癌症中心(NCIS)合作，共同探究ASLAN003作為單一療法和合併其他標靶藥物組合於治療血液腫瘤之潛能，並加速推進其化合物進入腫瘤臨床試驗。該合作計畫係由NCIS主任暨CSI副主任莊偉裕教授主導。其致力於研究識別惡性血液腫瘤，如白血病之有潛力的治療策略。亞獅康指出，ASLAN003為二氫乳清酸脫氫(酉每)的最佳小分子抑制劑，為催化哺乳動物細胞中嘧啶合成限速步驟之酵素。公司表示，ASLAN003針對多種腫瘤適應症開發，此化合物目前已完成第一期試驗，顯示良好的藥物動力學及耐受性。根據一篇於Cell發表的文章指出，二氫乳清酸脫氫(酉每)為急性骨髓性白血病的治療靶點。針對此次的合作，亞獅康營運長Mark McHale表示，莊偉裕教授及其臨床研究團隊有豐富經驗，擅於針對缺乏先進疾病治療之領域進行世界級尖端科學研究；相信與星國CSI和NCIS等研究機構合作將可促使內部加速開發出亞洲十大癌症之一的藥物。莊偉裕則表示，急性骨隨性白血病(AML)之醫療需求仍屬未被滿足；唯有約40%病患的病情能透過化療或幹細胞移植達到長期緩解，由於較為年長的病患無法承受此類十分強烈且有毒的治療，致使病況不甚樂觀，故研究團隊仍致力於尋找更新、更好且具有明確機轉基礎之療法。他進一步指出，ASLAN003為擁有良好耐受性以及令人振奮之臨床前結果的口服藥劑，希望與亞獅康合作後能迅速啟動此化合物的臨床試驗，並期望能使患者受益。

A new target for differentiation therapy in AML  Cell Research (2017) 27:9–10. doi:10.1038/cr.2016.130; published online 11 November 2016  Despite major advances in understanding the genetics and epigenetics of acute myelogenous leukemia, there is still a great need to develop more specific and effective therapies. High throughput approaches involving either genetic approaches or small molecule inhibitor screens are beginning to identify promising new therapeutic targets. One approach to develop new acute myelogenous leukemia (AML) therapies has been to design mechanism-based inhibitors. This has led to a number of new therapeutic agents entering clinical trials, including inhibitors of the DOT1L methyltransferase, BRD4 and IDH1/IDH21. This approach requires knowledge of the driver oncogenic mutation and is limited to specific genetic subtypes of AML. A further challenge is that other cooperating oncogenes may confer chemotherapy resistance. An alternative approach is to screen for agents that overcome the block to myeloid differentiation seen in AML. The most notable success was the discovery that trans retinoic acid (ATRA) induces differentiation of promyelocytic cell lines. This has led to the successful use of ATRA for patients with APL. But how can similar agents to overcome differentiation block for the other 90% of AML cases be identified?  Sykes et al. recently reported a powerful approach that should be broadly applicable to discovering new differentiation inducers in a wide range of AML cases. The authors noted that the homeobox-containing transcription factor HOXA9 is overexpressed in more than 50% of AML cases, including leukemias with MLL rearrangements, NUP98 translocations, NPM1 mutations and CDX2/CDX4 overexpression. Furthermore, this deregulation is important for leukemogenesis. The authors generated an inducible model of myeloid differentiation arrest by expressing an estrogen receptor-HoxA9 (ER-Hoxa9) fusion protein in murine bone marrow cells. Addition of β-estradiol (E2) to ER-Hoxa9-expressing cells induces the translocation of ER-HoxA into the nucleus thereby blocking myeloid differentiation. These immortalized cells were arrested at the granulocyte-macrophage progenitor (GMP) stage, but undergo synchronous and terminal neutrophil differentiation upon E2 withdrawal. To facilitate the screening of small molecules stimulating myeloid differentiation, Sykes et al. generated a Lys-GFP-ER-HOXA9 cell line with the inducible HOXA9 using knockin mice, in which GFP is inserted into the lysozyme locus. Lysozyme is only expressed in mature granulocytes, so that GFP expression serves as a reporter for screening compounds that induce differentiation. A library of 330 000 molecules was screened and of these, 12 induced myeloid differentiation. The activity of these was further tested in other AML lines and two with distinct chemical scaffolds (C03 and C07) were selected for optimization because of their activity in both murine and human AML cells. Identification of DHODH as a target for differentiation therapy. Myeloid cells were conditionally immortalized by expression of estrogen receptor-HoxA9 (ER-HOXA9) fusion protein in bone marrow cells in which GFP is inserted into the lysozyme locus. Removal of β-estradiol (E2) causes ER-HOXA9 to remain in the cytoplasm resulting in myeloid differentiation and expression of GFP and granulocyte markers such as CD11b. Screening 330 000 compounds led to the identification of small molecules promoting myeloid differentiation. Ultimately the target of the inhibitors was identified as DHODH, a key regulator of pyrimidine biosynthesis. The next challenge was to identify the protein target of the small molecules responsible for differentiating activity. The authors took the approach of growing the mouse and human cell lines for a long period in either C03 or C07 and analyzing the gene profiles of the drug-resistant cells by RNA-Seq. The resistant cells showed remarkably similar expression profiles, with up regulation of only eight shared genes that turned out to be located within a 100 Kb region of the long arm of human chromosome 16 or murine chromosome 8. One of these genes encoded dihydroorotate dehydrogenase (DHODH), a critical enzyme in uridine synthesis that catalyzes the conversion of dihydroorotate to orotate . Intriguingly, in addition to C03 and C07, all but one of the other 12 compounds identified in the small molecule screening were also found to be DHODH inhibitors.  These results strongly suggest that DHODH, and its downstream metabolic product uridine, regulate myeloid differentiation. This possibility is further supported by the finding that uridine can rescue the blockage of cell differentiation induced by DHODH inhibitors and that inhibiting orotidine 5′-phosphate decarboxylase, another essential enzyme regulating pyrimidine synthesis, causes a similar block in myeloid differentiation as that induced by the DHODH inhibitors.  The authors developed a lead compound ML390, derived from CO7, but it was found to be poorly bioavailable. Instead, for in vivo experiments, the authors chose a potent and selective inhibitor of DHODH, brequinar sodium (BRQ), which had been tested clinically for other tumors, but not leukemia. Encouragingly, BRQ treatment significantly induced myeloid differentiation, delayed the disease development and reduced the burden of leukemia-initiating cells in the various AML mouse models, including human cell line xenografts, patient-derived xenografts, and syngeneic mouse models caused by a variety of genetic alterations. The experimental approach of Sykes et al. is a powerful example of how high throughput strategies can be employed to identify new targets in AML and other malignancies. In particular the results show considerable promise for DHODH inhibitors, which have previously been used for treatment of other cancers, such as melanoma as well as rheumatoid arthritis and multiple sclerosis, for AML therapy. Notably, using a genetic approach, a CRISPR "dropout" screen, Tzelepis et al. found that a variety of AML cell lines are selectively vulnerable to DHODH depletion. While the precise targets affected by DHODH inhibition remain to be identified, since DHODH is required for UDP-GlcNAc formation and DHODH inhibition reduced protein O-linked N-glycosylation in the AML cells, the inhibitor effects may be mediated through reduced glycosylation of proteins regulating differentiation. There is no shortage of candidates involved. Proteins known to be regulated by GlcNAcylation include RNA polymerase II, transcription factors such as c-MYC, and epigenetic regulators such as the Polycomb protein RING1B6. Aside from further delineating this mechanism, it will be important to test how broadly DHODH inhibition is effective given the heterogeneity of human leukemias and also what drugs will be most successful in combination with DHODH inhibition for complete eradication of leukemia. 

References Stein EM, Tallman MS. Blood 2016; 127:71–78. Lo-Coco F, Avvisati G, Vignetti M, et al. N Engl J Med 2013; 369:111–121. Sykes DB, Kfoury YS, Mercier FE, et al. Cell 2016; 167:171–186. Collins CT, Hess JL. Oncogene 2016; 35:1090–1098. Tzelepis K, Koike-Yusa H, De Braekeleer E, et al. Cell Rep 2016; 17:1193–1205. Lewis BA, Hanover JA. J Biol Chem 2014; 289:34440–34448.